Literature DB >> 26179289

Renal Response in Patients with Chronic Kidney Disease Predicts Outcome Following Cardiac Resynchronization Therapy.

Gaurav Singal1, Gaurav A Upadhyay2,3, Rasmus Borgquist2,4, Daniel J Friedman1, Neal A Chatterjee1, Jagdesh Kandala2,3, Mi Young Park3, Mary Orencole2,3, George W Dec3, Michael H Picard3, Jagmeet P Singh2,3, Theofanie Mela2,3.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) severity is associated with increased morbidity and mortality in congestive heart failure. There is a paucity of data regarding renal improvement after cardiac resynchronization therapy (CRT) and its potential impact on clinical outcomes, especially in patients with severe CKD.
METHOD: This was a retrospective analysis of a prospectively collected cohort of 260 patients with CKD undergoing CRT at a single center. Renal function was compared before and after CRT. The primary end point was a composite of death, heart transplant, and left ventricular assist device (LVAD), assessed at 5 years.
RESULTS: Patients with more severe CKD demonstrated increased risk of death, transplant, or LVAD following CRT (P = 0.015). Renal response (estimated glomerular filtration rate improvement ≥10 mL/min/1.73 m(2) ) was observed in 14% of all patients and 28% of patients with stage IV CKD. Independent predictors of renal response included left ventricular ejection fraction improvement (odds ratio [OR] 1.06, confidence interval [CI] 1.01-1.10), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use (OR 4.31, CI 1.08-17.23), and advanced CKD stage (OR 2.19, CI 1.14-4.23). Renal response independently decreased hazard of the primary outcome (HR 0.24, CI 0.08-0.73, P = 0.01). Renal responders with stage IV CKD had 80% 5-year event-free survival, compared to 0% for nonrenal responders in stage IV (P = 0.03).
CONCLUSION: Although severity of CKD is associated with poorer outcome after CRT, improvement in renal function can occur in patients across all CKD stages. Renal responders, including those with stage IV CKD, demonstrate favorable 5-year outcomes. Assessment of renal response may help better prognostic outcomes following CRT.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac resynchronization therapy; cardiorenal syndrome; chronic kidney disease; heart failure; pacemakers

Mesh:

Year:  2015        PMID: 26179289     DOI: 10.1111/pace.12685

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  4 in total

1.  Response and outcomes of cardiac resynchronization therapy in patients with renal dysfunction.

Authors:  Rita Ilhão Moreira; Pedro Silva Cunha; Pedro Rio; Manuel Nogueira da Silva; Luísa Moura Branco; Ana Galrinho; Joana Feliciano; Rui Soares; Rui Cruz Ferreira; Mário Martins Oliveira
Journal:  J Interv Card Electrophysiol       Date:  2018-02-19       Impact factor: 1.900

2.  Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function.

Authors:  Patrick H Pun; Shubin Sheng; Gillian Sanders; Adam D DeVore; Daniel Friedman; Gregg C Fonarow; Paul A Heidenreich; Clyde W Yancy; Adrian F Hernandez; Sana M Al-Khatib
Journal:  Am J Cardiol       Date:  2016-12-18       Impact factor: 2.778

3.  Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study.

Authors:  Quynh A Truong; Jackie Szymonifka; James L Januzzi; Jigar H Contractor; Roderick C Deaño; Neal A Chatterjee; Jagmeet P Singh
Journal:  Heart Rhythm       Date:  2018-12-24       Impact factor: 6.343

Review 4.  Impact of baseline renal function on all-cause mortality in patients who underwent cardiac resynchronization therapy: A systematic review and meta-analysis.

Authors:  G Bazoukis; K P Letsas; P Korantzopoulos; C Thomopoulos; K Vlachos; S Georgopoulos; N Karamichalakis; A Saplaouras; M Efremidis; A Sideris
Journal:  J Arrhythm       Date:  2017-05-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.